Alexion Pharmaceuticals, a subsidiary of AstraZeneca based in Boston, Massachusetts, is dedicated to developing orphan drugs for the treatment of rare diseases. The company focuses on creating innovative therapies that provide meaningful value to patients and their families, helping them live their best lives despite their conditions. Alexion's mission is driven by the needs of people living with rare and devastating diseases, guiding their continuous efforts in pharmaceutical innovation.

Alexion has made significant strides in the field of rare disease treatment, contributing groundbreaking therapies that have transformed patient care. Their portfolio includes life-changing medications that address conditions like hypophosphatasia (HPP) and other rare disorders. As a recognized leader in the pharmaceutical industry, Alexion's work has garnered attention and investment from major entities, solidifying its impact on global health and patient outcomes.